Novel Infringed Braintree's Laxative Patent, Judge Rules

Law360, New York (January 22, 2013, 3:05 PM EST) -- A New Jersey federal judge ruled Friday that Novel Laboratories Inc., a company that planned to make a generic of the colon-cleansing drug Suprep, infringed Braintree Laboratories Inc.'s patent on the branded version of the medication.

U.S. District Judge Peter G. Sheridan granted summary judgment in favor of Braintree, finding that Novel's plans to make generic Suprep — a laxative used to clear the colon in preparation for a colonoscopy — would infringe U.S. Patent Number 6,946,149, as well as contribute to and induce infringement by...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.